Drugs in the Pipeline, News
Tofacitinib Ext-Rel Monotherapy Effective for Moderate to Severe RA After Methotrexate Withdrawal
The ORAL Shift study enrolled 694 RA patients who were inadequate responders to methotrexate alone.
Your search for tofacitinib returned 18 results
Drugs in the Pipeline
Tofacitinib Effective in Phase 3 Psoriasis Retreatment Study
Pfizer announced results from the OPT (Oral treatment Psoriasis Trial) Retreatment study (A3921111) assessing tofacitinib for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
Drugs in the Pipeline
Xeljanz Demonstrates Efficacy in Third Phase 3 Ulcerative Colitis Study
Pfizer announced top-line results from OCTAVE Sustain, the third Phase 3 study of Xeljanz (tofacitinib citrate) for the potential treatment of patients with moderately to severely active ulcerative colitis (UC).
Drugs in the Pipeline
Tofacitinib Demonstrates Efficacy for Potential UC Indication
Pfizer announced top-line results from two Phase 3 induction trials of tofacitinib for the treatment of adults with moderate to severe ulcerative colitis (UC).
Drugs in the Pipeline
Xeljanz Demonstrates Efficacy in Chronic Plaque Psoriasis
Pfizer announced results from OPT Compare (A3921080), a Phase 3 study of Xeljanz (tofacitinib) for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
Drugs in the Pipeline
Positive Results for Oral Tofacitinib in Ulcerative Colitis Presented
Pfizer announced detailed results from the first 2 pivotal Phase 3 trials of the OCTAVE program evaluating oral tofacitinib 10mg twice daily in inducing remission in adults with moderately to severely active ulcerative colitis (UC). Findings were orally presented at the 11th Congress of ECCO Scientific Session.
Drugs in the Pipeline
Phase 3 Trial Update of Tofacitinib for Rheumatoid Arthritis
Pfizer announced top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib in the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).
Drugs in the Pipeline
Phase 3 Study of Tofacitinib for Rheumatoid Arthritis
Pfizer announced results from its Phase 3 study of tofacitinib, formerly known as tasocitinib, for the treatment of patients with rheumatoid arthritis (RA).
Drugs in the Pipeline
Tofacitinib Meets Endpoints in Two Phase 3 Psoriasis Trials
Pfizer announced top-line results from two pivotal Phase 3 trials, evaluating the efficacy and safety of Xeljanz (tofacitinib) for the treatment of moderate-to-severe plaque psoriasis.
Drugs in the Pipeline
Complete Response Letter Issued for Xeljanz on New Indication
The FDA has issued a Complete Response Letter (CRL) for the supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate; Pfizer) for the treatment of adults with moderate to severe chronic plaque psoriasis.
